A catered lunch will be provided at 12:30pm. Please RSVP to email@example.com by COB Friday 31 May.
Kirby Institute Seminar Series presents
The introduction of direct-acting antiviral (DAA) therapy has transformed the clinical management of hepatitis C virus (HCV) infection and given impetus to the WHO goal of eliminating HCV infection as a public health threat by 2030. Although DAA therapy has provided the tools to achieve this, HCV elimination is contingent on substantially increasing the number of people tested, diagnosed, linked to care and treated. Improving the HCV care cascade among marginalised high-risk populations of people who inject drugs and people who are homeless is paramount in these efforts. This seminar presents findings from the evaluation of the feasibility and outcomes of strategies to enhance the HCV care cascade among marginalised populations pre- and post-access to DAA therapy.